ArticleEuropean journal of medical research2025
Serum soluble transferrin receptor (sTfR) in HFpEF: associations with cardiac function and exercise tolerance.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the potential links between soluble transferrin receptor (sTfR), the monocyte/HDL cholesterol ratio (MHR), and heart failure with preserved ejection fraction (HFpEF), in order to provide new biomarkers for clinical evaluation of HFpEF and new ideas for disease treatment.
method66 patients diagnosed with HFpEF who visited the cardiology department of Cangzhou Central Hospital from January 2023 to October 2023 were selected as the study group, and 70 healthy participants from concurrent physical examinations at the hospital's examination center were designated as controls. Record demographic data, hematological/biochemical parameters (including sTfR, MHR), and echocardiographic measures of cardiac structure and function. Compare these indices between groups to assess for statistically significant differences. Conduct a multi-factor analysis of the risk factors obtained from the single factor analysis above to explore the independent risk factors of HFpEF. Conduct subgroup analysis on the research group to explore the correlation between sTfR and cardiac structure, function, and activity tolerance in HFpEF patients. Follow up with the patients in the research group for 1 year and analyze their prognosis.
resultFemale representation (69.7% vs 51.4%), left atrial diameter (37.52 ± 3.57 mm vs 35.04 ± 2.83 mm), and sTfR [3.29 (2.76, 3.57) mg/L vs 2.43 (2.08, 2.78) mg/L] were significantly greater in the study group compared to the control group across both cohorts (P < 0.05); There were no significant intergroup differences in terms of age, demographic and clinical histories (smoking, alcohol use, hypertension, diabetes), blood lipid profile, hepatic and renal function, other biochemical parameters, or MHR (P > 0.05 for all). Multivariable analysis identified sTfR (OR 1.293, P = 0.012) and LAD (OR 15.229, P < 0.01) as independent risk factors for HFpEF. Their predictive performance, assessed by ROC curve analysis, yielded AUC values of 0.835 for sTfR and 0.609 for LAD. The corresponding optimal diagnostic thresholds for predicting HFpEF were 3.05 mg/L and 37.5 mm, respectively. Subgroup analysis revealed significantly higher BNP and LAD, but lower 6MWT, in patients with high versus low sTfR expression (all P < 0.05). Over the 1-year follow-up, cumulative event-free survival did not differ significantly between patients with high versus low sTfR expression (median 11.17 vs. 11.65 months; Log-Rank χ
conclusionSerum sTfR correlates with HFpEF severity and prognosis, offering a potential biomarker for disease assessment and outcome prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.